

Tuberculosis profile: Maldives

Population 2022: 0.52 million

Estimates of TB burden*, 2022

	Number	(Rate per 100 000 population)
Total TB incidence	200 (160-260)	39 (30-49)
HIV-positive TB incidence	0 (0-3)	0 (0-0.64)
MDR/RR-TB incidence**	2 (0-4)	0.41 (0-0.85)
HIV-negative TB mortality	9 (8-10)	1.7 (1.5-1.9)
HIV-positive TB mortality	0 (0-0)	0 (0-0)

Estimated proportion of TB cases with MDR/RR-TB*, 2022

New cases	0.88% (0.2-2.3)
Previously treated cases	6.4% (0.34-24)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2022	54% (43-71)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2022	4% (3-6)

TB case notifications, 2022

Total new and relapse	111
- % tested with rapid diagnostics at time of diagnosis	37%
- % with known HIV status	77%
- % pulmonary	33%
- % bacteriologically confirmed ^	100%
- % children aged 0-14 years	5%
- % women (aged ≥15 years)	27%
- % men (aged ≥15 years)	68%
Total cases notified	111

TB/HIV care in new and relapse TB patients, 2022

	Number	(%)
Patients with known HIV status who are HIV-positive	0	0%
- on antiretroviral therapy	0	

Drug-resistant TB care***, 2022

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	76%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	
Laboratory-confirmed cases - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	1
Patients started on treatment - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^^	1
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	0
Patients started on treatment - pre-XDR-TB or XDR-TB ^^	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	0

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2021	77%	87
Previously treated cases, excluding relapse, registered in 2021		0
HIV-positive TB cases registered in 2021		0
MDR/RR-TB cases started on second-line treatment in 2020	0%	1
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2020		0

TB preventive treatment, 2022

% of HIV-positive people (newly enrolled in care) on preventive treatment	0%
% of household contacts of bacteriologically-confirmed TB cases on preventive treatment	7.9% (7.7-8.1)

* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.


** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone

^ Calculated for pulmonary cases only


^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2022 and patients who were not laboratory-confirmed


Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)



HIV-negative TB mortality (Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2022



Cases attributable to five risk factors, 2022

